GALECTIN THERAPEUTICS INC. (GALT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 151.62M USD | Liabilities, Current |
| Cash and equivalents | 13.27M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $151.62M | $13.27M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $7.31M | $14.11M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $8.03M | $17.72M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $136.44M | $11.53M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $10.77M | $13.77M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $110.84M | $7.43M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $35.41M | $15.12M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $25.26M | $27.06M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $14.62M | $25.60M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $12.63M | $23.55M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $15.68M | $25.66M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $10.52M | $20.36M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $9.95M | $17.97M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $11.53M | $17.80M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $13.01M | $18.59M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $9.59M | $15.83M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $10.89M | $24.18M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $9.54M | $31.61M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $9.03M | $39.65M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $8.30M | $36.60M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $6.05M | $31.60M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $4.66M | $20.76M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $5.40M | $27.14M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $2.49M | $32.56M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $4.28M | $40.77M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.32M | $43.33M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.82M | $47.48M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $1.22M | $50.34M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.32M | $52.04M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $907.00K | $6.97M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.11M | $8.25M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $1.65M | $10.14M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $1.44M | $10.50M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $2.28M | $3.99M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $2.97M | $3.05M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $4.34M | $6.96M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $3.51M | $9.13M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $4.36M | $13.64M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $3.78M | $15.36M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $4.09M | $16.06M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $3.64M | $18.00M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $3.25M | $22.36M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.36M | $25.85M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $21.32M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $26.36M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $1.29M | $29.35M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.70M | $29.13M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $1.38M | $31.20M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $2.15M | $34.42M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $1.94M | $36.59M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.49M | $10.49M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $1.60M | $9.71M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $1.49M | $5.10M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $1.47M | $7.02M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.64M | $9.36M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $1.44M | $11.06M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $1.78M | $13.13M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $2.13M | $15.31M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $2.21M | $6.40M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $815.00K | $7.94M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $786.00K | $7.98M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $6.95M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.77M | $5.89M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $2.81M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $2.86M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $251.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |